Showing 4751-4760 of 8898 results for "".
- FDA Nod for Stelara in Pediatric Psoriatic Arthritishttps://practicaldermatology.com/news/fda-nod-for-stelara-in-pediatric-psoriatic-arthritis/2461284/The FDA approved Stelara (ustekinumab) for the treatment of pediatric patients six years of age and older with active psoriatic arthritis (PsA). Stelara is a fully human monoclonal antibody that selectively inhibits both interleukin (IL)-12 and IL-23, two cytokines thought to
- Zoryve from Arcutis Approved for Plaque Psoriasishttps://practicaldermatology.com/news/zoryve-from-arcutis-approved-for-plaque-psoriasis/2461282/FDA has approved the New Drug Application (NDA) for Zoryve (roflumilast) cream 0.3% from Arcutis Biotherapeutics for the treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age or older. The first and only topical phosphodiesterase-4 (PDE4) inhib
- Aesthetics Biomedical Adds to Leadership Team to Fuel Growth Trajectoryhttps://practicaldermatology.com/news/aesthetics-biomedical-adds-to-leadership-team-to-fuel-growth-trajectory/2461280/In an ongoing efforts to meet the increasing demand for its aesthetic products and distribution growth, Aesthetics Biomedical Inc. (ABM), is continuing to build its executive team with the recent hires of industry experts Derek Harmon as Vice President of U.S. Sales and Don Selvey, NMD, MS as Vic
- Almirall Launches New Call for Innovative Therapies for Skin Diseaseshttps://practicaldermatology.com/news/almirall-launches-new-call-for-innovative-therapies-for-skin-diseases/2461279/Almirall SA has launched its seventh call for proposals to establish collaborations in dermatological research through AlmirallShare, it
- CHMP Recommends European Approval of Nivolumab/Relatimab for Certain Melanomashttps://practicaldermatology.com/news/chmp-recommends-european-approval-of-nivolumabrelatimab-for-certain-melanomas/2461278/The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of
- Physician Growth Partners Advises MetroDerm PC in Partnership with United Derm Partnershttps://practicaldermatology.com/news/physician-growth-partners-advises-metroderm-pc-in-partnership-with-united-derm-partners/2461277/Physician Growth Partners (PGP) has advised
- Incyte's Opzelura Adds Vitiligo Indicationhttps://practicaldermatology.com/news/incytes-opzelura-adds-vitiligo-indication/2461274/Opzelura™ (ruxolitinib) cream 1.5% from Incyte is now approved for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older. Opzelura is the first and only FDA-approved treatment for repigmentation in patients with vitiligo and the only topica
- FDA Clears Use of Apyx Medical’s Renuvion Handpiece for Improvement in Appearance of Lax Skinhttps://practicaldermatology.com/news/fda-clears-use-of-apyx-medicals-renuvion-to-improve-appearance-of-lax-skin/2461273/The U.S. Food and Drug Administration received 510(k) clearance for the use of Apyx Medical’s Renuvion APR Handpiece for certain skin contraction procedures. Specifically, the Renuvion APR Handpieces are now indicated for use in subcutaneous dermatological and aest
- DermTech Appoints Two New Board Membershttps://practicaldermatology.com/news/dermtech-appoints-two-new-board-members/2461272/DermTech, Inc. appointed Kirk D. Malloy, Ph.D. and Mark C. Capone, M.S. to the Company’s board of directors, effective July 18,2022. These appointments expand DermTech’s board of directors to eight members. “We are excited to welco
- Dermaliq Forms New Scientific and Medical Advisory Boardhttps://practicaldermatology.com/news/dermaliq-forms-new-scientific-and-medical-advisory-board/2461270/Dermaliq Therapeutics, Inc. has formed a Scientific and Medical Advisory Board. New members include Gordon Dow, Xavier Yon, Michael Kuligowski, MD, PhD, and R. Todd Plott, MD. The Advisory Board is composed of key clinical investigators and industry veterans in the field who suppor